Neoadjuvant FOLFIRINOX <italic>versus</italic> neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

doi:false

Join BJS Academy

Home
BJS Academy
BJS Academy
The BJS Academy is the educational arm of the BJS Foundation. A hub to meet, learn, be mentored, discuss, listen and understand the education and accreditation opportunities available
Discover the BJS Academy
Continuing surgical education
Young BJS
Cutting edge blog
Surgical news
Scientific surgery
Randomized clinical trials
Surgical trials
Surgical science
Social media
Surgery for all
BJS Journals
BJS Journals
The BJS Foundation owns complementary surgical publications, BJS and BJS Open, renowned for the exceptional quality of their peer review and editorial processes.
Published online, BJS is a monthly subscription journal containing a combination of open access and subscriber only articles. Online publication, BJS Open, is produced bi-monthly and contains only open access articles.
Discover the BJS Journals
BJS
BJS Open
BJS Institute
BJS Partners
BJS Partners
The BJS Foundation’s strategic partner collaboration is a fantastic opportunity for like-minded organisations to work together to achieve shared goals and ambitions.
Strategic partners can benefit from a range of financial and non-financial benefits for their organisation and membership, including a heavily discounted subscription to the BJS.

Our BJS Partners
Educational Partners
Development Partners
Partner Societies
Strategic Partners
Partner overview opportunities
BJS Award
About
About
The BJS Foundation is a charitable body with a mission to advance and improve education in surgery and to diffuse knowledge on new and improved methods of teaching and practicing surgery in all branches.
Find out more about us
Council of Management
Executive Committee
Sub-Committees
Editorial teams
Editorial board
BJS Academy team
Charitable activities
Editorial apprenticeships

Normal View Dyslexic View

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

9 January 2026

HPB

BJSA

BJS Academy

0000-0000

BJS Foundation Limited

London, UK

BJS-2026-0008

Randomized Clinical Trials

HPB

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

09012026

Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP et al, for the Dutch Pancreatic Cancer Group.

Lancet Oncol 2025; 26: 1346-1356.

This study included 375 patients and found similar median overall survival between the two neoadjuvant chemotherapy regimens: 21.9 months after FOLFORINOX versus 21.3 months after gemcitabine-based chemotherapy.

Comment: The optimal regimen remains uncertain.

Article info

Published on: 9 January 2026

Article ID: BJS-2026-0008

Home

Info

Copied!

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Connect

Contact

Connect

About

Company

BJS Academy

BJS Journals

BJS Partners

About

Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

Related articles

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Connect

Contact

Connect

About

Company